Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the agreement, Y.S.P. will develop and commercialize TaiGen's new small molecule drug, TG-1000, a virus replication inhibitor, for infections, in Malaysia and Singapore.
Lead Product(s): TG-1000
Therapeutic Area: Infections and Infectious Diseases Product Name: TG-1000
Highest Development Status: Phase IIProduct Type: Small molecule
Recipient: TaiGen Biotechnology
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement October 10, 2023